This research further demonstrates that the relative abundance of Akk in the gut and feces may represent potential biomarkers to refine patient stratification and contribute to the treatment of NSCLC via ICIs targeting the PD-1/PD-L1 axis. This evidence concerns the gene CD274 and non-small cell lung carcinoma.